Trial reportEuropean journal of cancer (Oxford, England : 1990)2021
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.
Trial report in European journal of cancer (Oxford, England : 1990), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04365322 (Étude Des réponses Immunitaires Lymphocytaires spécifiques Chez Des Patients infectés Par le Virus SARS-CoV-2), which is not on this map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Étude Des réponses Immunitaires Lymphocytaires spécifiques Chez Des Patients infectés Par le Virus SARS-CoV-2 : Caractéristiques Des Réponses Effectrices et Mémoires
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Pooled it
- Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.Frontiers in oncology · 2021Pooled it
- Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses.Human vaccines & immunotherapeutics · 2025Article
- SARS-CoV-2 Ct values and COVID-19 symptoms in patients with haematological malignancies in South Africa.Southern African journal of infectious diseases · 2025Article
- Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19.Blood advances · 2024Article
- COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?Metabolites · 2024Review
- Article
- Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.BMJ oncology · 2023Article
- COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review.Therapeutic advances in vaccines and immunotherapy · 2023Review
- Colorectal cancer in patients with SARS-CoV-2: a systematic review and meta-analysis.Infectious agents and cancer · 2022Article
- Article
- Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments.European journal of cancer (Oxford, England : 1990) · 2022Article
- Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients.European journal of cancer (Oxford, England : 1990) · 2022Article
- Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection.Translational research : the journal of laboratory and clinical medicine · 2022Review
- Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.Nature communications · 2022Article
- Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.Cancer discovery · 2022Review
- Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article.European journal of cancer (Oxford, England : 1990) · 2022Review
- SARS-CoV-2 vaccines: What we know, what we can do to improve them and what we could learn from other well-known viruses.AIMS microbiology · 2022Article
- SARS-CoV-2 persistence in immunocompromised children.Pediatric blood & cancer · 2021Article
- Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.European journal of cancer (Oxford, England : 1990) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus.
methodsWe have started a prospective monocentric trial entitled COV-CREM (NCT04365322) in April 2020. The primary objective of the trial was to assess specific immune response's intensity and diversity to SARS-CoV-2 in infected patients.
resultsIn this study, we showed that cancer patients (28 solid tumours, 11 haematological malignancies) exposed to SARS-CoV-2 produced a high rate of specific antibodies, as observed in patients without a cancer history (n = 29). However, our results highlight a lack in the generation of T-cell responses against CoV-N, M and S proteins from the SARS-CoV-2 virus, suggesting that cancer patients failed to mount a protective T-cell immunity. Nevertheless, SARS-CoV-2 infection did not impair established immune memory since specific responses against common viruses were not hampered in cancer patients.
conclusionGiven the severity and the unknown evolution of the ongoing COVID-19 pandemic, it is of fundamental importance to integrate cancer patients in vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.